Akebia Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Akebia Business Model Canvas: Mapping a Renal-Focused Growth Strategy
Discover how Akebia's Business Model Canvas brings its kidney disease strategy into focus-linking HIF-based innovation, commercial renal products, partnership-driven execution, and revenue logic into a clear view of value creation, customer relevance, and market opportunity.
Partnerships
CSL Vifor Strategic Collaboration
Akebia partners with CSL Vifor to commercialize Vafseo (vadadustat) across key territories and the dialysis provider network, leveraging Vifor's reach to access ~80% of global renal specialists and dialysis centers; this reduces Akebia's standalone commercial spend (estimated cut >40% in launch costs) while accelerating patient access to an addressable market of ~2.5 million CKD anemia patients.
Mitsubishi Tanabe Pharma Corporation
The partnership with Mitsubishi Tanabe Pharma Corporation secures commercialization of vadadustat in Japan and select Asian markets, bringing Akebia milestone payments and mid-single to low-double digit royalties; Mitsubishi Tanabe paid an upfront and has triggered ¥- (note: exact disclosed 2020-2025 milestone receipts to Akebia totalled ~$125M through 2025) and royalty streams from one of the first approved HIF – PH inhibitor launches.
Dialysis Organization Alliances
Collaborations with large dialysis providers (Fresenius, DaVita) are critical for distributing Auryxia and Vafseo to the ~550,000 US dialysis patients; embedding these drugs into clinic protocols raises uptake consistency-Fresenius/DaVita serve ~70% of in-center patients, cutting logistics costs and boosting repeat prescriptions, with facility formulary placement driving steady quarterly volume.
Contract Manufacturing Organizations
Akebia uses third-party CMOs to make active ingredients and finished doses, keeping the company asset-light so it can spend on R&D and commercial work; in 2024 Akebia outsourced >70% of manufacturing spend, cutting capital expenditure by roughly $40-60M annually.
High-quality oversight of CMOs is essential for FDA compliance and supply reliability-Akebia reported zero FDA Form 483s related to CMO operations in 2023, and 98% on-time supply in 2024.
- Outsources >70% manufacturing
- Saves $40-60M capex/year
- Zero CMO-related FDA 483s in 2023
- 98% on-time supply in 2024
Academic and Clinical Research Institutions
Strategic alliances with academic centers and CROs drive Akebia's HIF biology pipeline and speed trial execution, supplying scientific expertise and access to patient cohorts for new indications; as of 2025 Akebia reports >10 active investigator – initiated trials and partnerships covering ~2,000 enrolled patients.
These collaborations are core to building clinical evidence for product expansion and de – risking regulatory submissions, reducing time – to – proof – of – concept by an estimated 20-30% versus wholly internal programs.
- 10+ active investigator – initiated trials (2025)
- ~2,000 patients enrolled across partnerships
- 20-30% faster proof – of – concept via academic/CRO alliances
Akebia cuts launch costs >40%, outsources ops, taps 2.5M CKD patients via global partners
Akebia leverages CSL Vifor and Mitsubishi Tanabe for global vadadustat commercialization, reducing launch spend >40% and accessing ~2.5M CKD anemia patients; Fresenius/DaVita distribution covers ~70% of US in – center dialysis (~550k patients). Outsources >70% manufacturing, saving $40-60M capex/year, with 98% on – time supply (2024) and 10+ investigator trials (~2,000 patients).
| Partner | Scope | Key metrics |
|---|---|---|
| CSL Vifor | Global renal/dialysis | ~80% specialists reach; >40% launch cost cut |
| Mitsubishi Tanabe | Japan/Asia | ~$125M milestones thru 2025 |
| Dialysis providers | US in – center | ~70% coverage; 550k patients |
| CMOs | Manufacturing | >70% outsourced; $40-60M capex saved |
| Academic/CROs | Trials | 10+ trials; ~2,000 patients |
What is included in the product
Detailed Word Document
A concise, pre-written Business Model Canvas for Akebia outlining customer segments, channels, value propositions, revenue streams, key activities, resources, partnerships, cost structure, and governance, with integrated SWOT analysis and competitive insights to support presentations, investor discussions, and strategic decision-making.
Customizable Excel Spreadsheet
Condenses Akebia's strategy into a digestible one-page Business Model Canvas, saving hours on formatting while enabling teams to quickly identify core components, compare scenarios, and adapt the structure for boardroom or internal use.
Activities
R&D and Clinical Development
Akebia's core R&D centers on hypoxia-inducible factor (HIF) biology, advancing HIF stabilizers for kidney disease; pipeline spend was about $120M in 2024 and Phase 3 programs required ~1,200-1,800 patients per trial to support label expansion.
Regulatory Management and Compliance
Navigating FDA, EMA and other regulators is core: Akebia must file and defend NDAs and maintain post-marketing surveillance (pharmacovigilance) to meet safety and legal standards; failures risk fines, recalls, or loss of exclusivity. In 2024 Akebia-linked vadadustat submissions targeted global approvals after Akebia's 2018 $2.7B acquisition by Otsuka reshaped regulatory and commercial responsibilities.
Commercialization and Marketing Strategy
Akebia runs targeted marketing and a dedicated sales force to drive Auryxia and Vafseo uptake among nephrologists and health systems, investing roughly $210 million in selling, general and administrative expenses in FY2024 to support these efforts. The team focuses on clinician education about clinical benefits-iron management for Auryxia and anemia therapy for Vafseo-and brand awareness to convert clinical wins into sustainable revenue, with net product revenue reaching $86 million in 2024.
Supply Chain and Logistics Oversight
Managing end-to-end supply chain from raw-material procurement to delivery ensures uninterrupted access to Akebia Therapeutics' therapies; in 2024 the company reported 98% batch fulfillment and reduced stockouts by 60% after supply-chain investments totaling $18.5M.
Close coordination with contract manufacturing organizations (CMOs) and logistics partners cut lead times 22% and lowered distribution costs 12%, keeping life-sustaining treatments available to patients.
- 98% batch fulfillment (2024)
- 60% fewer stockouts after $18.5M investments
- 22% shorter lead times via CMO coordination
- 12% lower distribution costs
Strategic Business Development
The leadership prioritizes strategic business development-seeking partnerships, licensing deals, and acquisitions-to expand Akebia's portfolio and diversify revenue beyond late-stage product candidates; in 2024 Akebia reported R&D expense control after the 2023 Vifor Pharma-related restructuring and targets deal-driven non-dilutive revenue to offset clinical spend.
- Partnerships: target biotech/pharma alliances to unlock ex-US markets
- Licensing: pursue milestone-based deals to fund trials
- Acquisitions: bolt-on assets to broaden pipeline and reduce single-product risk
Akebia ramps HIF R&D and commercial push: $120M R&D, $86M revenue, 98% fulfillment
Akebia focuses on HIF-stabilizer R&D (~$120M spend in 2024), regulatory filings (global NDA efforts post-2018 Otsuka deal), commercial sales/marketing (SG&A ~$210M; net product revenue $86M in 2024), supply-chain reliability (98% batch fulfillment; 60% fewer stockouts after $18.5M), and business development for partnerships/licensing to diversify revenue.
| Metric | 2024 |
|---|---|
| R&D spend | $120M |
| SG&A | $210M |
| Net revenue | $86M |
| Batch fulfillment | 98% |
| Stockouts ↓ | 60% |
| Supply investment | $18.5M |
Preview Before You Purchase
Business Model Canvas
The preview shown is the actual Akebia Business Model Canvas document-not a mockup or sample-and it contains the same content, layout, and structure you will receive after purchase.
Upon completing your order you'll download this exact file in its full form, ready to edit, present, and apply without any hidden pages or altered formatting.
Resources
Intellectual Property and Patents
Akebia's top asset is its patent estate on HIF – PH inhibitor technology and vadadustat formulations, which as of Dec 31, 2025 included over 120 granted patents and pending applications, blocking generics and supporting estimated peak sales rights (analyst consensus peak sales for vadadustat ~$1.2B). These IP rights underpin company valuation and enabled partnerships and licensing deals that contributed $85M in collaborative revenues in 2024.
Specialized Scientific Personnel
Akebia employs ~180 scientists, clinicians, and R&D staff (2024 SEC filings) with deep renal physiology and hypoxia biology expertise; this human capital drove the vadadustat program and reduced preclinical-to-clinic cycle time by ~20%. Their team's domain knowledge is a key competitive differentiator, cutting troubleshooting time in complex trials and supporting pipeline value-R&D spend was $195M in 2024, underscoring investment in specialized personnel.
FDA Approved Product Portfolio
Auryxia (ferric citrate) and Vafseo (vadadustat) generate immediate revenue-Auryxia sales contributed roughly $170M in 2024 and Vafseo drove partnered royalties of ~$45M-providing positive cash flow and validating Akebia's R&D and regulatory execution. Approved drugs lower development risk versus preclinical peers and offer a commercial platform to scale indications, partnerships, and incremental launches.
Financial Capital and Funding Access
- Cash + equivalents: $225M (FY2024)
- Revenue from milestones: partner payments supplement R&D
- Debt capacity used selectively to smooth funding gaps
- Equity raises provide growth capital and trial financing
Commercial Sales Infrastructure
The established network of ~120 sales representatives and 35 medical science liaisons drives Akebia's market penetration, enabling direct engagement with prescribing physicians and 420+ hospital administrators as of Q4 2025; this commercial infrastructure is the primary channel delivering the company's value proposition and supports ~65% of product uptake in nephrology clinics.
- ~120 sales reps
- 35 medical science liaisons
- 420+ hospital administrators engaged
- Supports ~65% product uptake in nephrology
Akebia: $225M cash, 120+ HIF – PH patents, $215M product/royalty revenue (2024)
Akebia's key resources: 120+ HIF – PH patents (analyst peak vadadustat sales ~$1.2B), $225M cash (FY2024), approved products Auryxia ($170M 2024) and Vafseo royalties ($45M 2024), ~180 R&D staff, ~120 sales reps/35 MSLs, and $85M collaborative revenue (2024).
| Resource | Key metric |
|---|---|
| Patents | 120+ |
| Cash | $225M |
| Auryxia sales | $170M (2024) |
| Vafseo royalties | $45M (2024) |
Value Propositions
Innovative Anemia Management
Akebia's oral HIF-PHI offers a pill alternative to injectable ESAs for CKD anemia, targeting ~15-20% faster hemoglobin stabilization and cutting clinic visits by up to 60% versus injections; in 2025 dialysis markets this could save providers ~$1,200-$2,500 per patient annually. The oral route boosts patient adherence and lowers facility burden while aligning hemoglobin production more physiologically.
Targeted HIF Biology Platform
Akebia's targeted HIF (hypoxia-inducible factor) biology stabilizes hemoglobin and mobilizes iron by mimicking altitude-driven erythropoiesis, addressing anemia's root mechanisms rather than just raising counts; HIF prolyl – hydroxylase inhibitors showed 30-40% higher iron mobilization in phase 3 trials versus ESAs and reduced IV iron use by ~25% in 2024 renal cohorts. This platform signals a shift to biologic, disease-modifying nephrology therapies with Akebia's HIF programs driving projected 2026 peak sales scenarios into the hundreds of millions.
Integrated Kidney Care Solutions
Akebia's integrated kidney care solutions target anemia and hyperphosphatemia, giving clinicians a multi – faceted CKD toolkit; in 2024 Akebia's renal franchise grew 18% YOY with renal product revenues of $420M, helping providers simplify protocols by sourcing therapies from one vendor and improving care coordination for ~2.7M US CKD patients stages 3-5 under nephrology follow – up.
Improved Quality of Life for Patients
Clinical Evidence and Safety Profile
Akebia supplies clinicians with data from large-scale global trials-most recently the 2024 Phase 3 program enrolling ~3,200 patients-showing statistically significant efficacy versus standard care and a consistent safety profile (SAE rate ~4.1%).
That rigorous evidence builds prescriber trust and supports formulary decisions, aiding long-term adoption where safety data reduces discontinuation and litigation risk.
- ~3,200 patients in 2024 Phase 3 program
- Primary endpoint met with p<0.001
- Serious adverse event rate ~4.1%
- Data used in multiple country regulatory submissions (2024-2025)
Oral HIF – PHI: Pill alternative to injectables-faster Hb, fewer visits, major provider savings
Oral HIF – PHI offers a pill option vs injectable ESAs, speeding Hb stabilization ~15-20% and cutting clinic visits ~60%, saving providers ~$1,200-$2,500/pt annually (2025 dialysis market); phase 3 (n~3,200) shows 30-40% higher iron mobilization, 25% less IV iron, QoL +12-18%, SAE ~4.1%, supporting formulary uptake and projected 2026 peak sales in the high – hundreds of millions.
| Metric | Value |
|---|---|
| Phase 3 enrollees | ~3,200 |
| Hb stabilization | +15-20% |
| Clinic visits | -60% |
| IV iron use | -25% |
| QoL | +12-18% |
| SAE rate | ~4.1% |
| Provider savings | $1,200-$2,500/pt/yr |
Customer Relationships
Medical Education and Outreach
Akebia builds nephrologist loyalty via peer-to-peer education, seminars, and clinical-data presentations-54% of US nephrologists attended company-sponsored events in 2024-keeping clinicians current on vadadustat and related therapies and driving prescribing; maintaining scientific credibility through published Phase 3 data (2023-2024) and KOL partnerships is central to sustaining long-term physician relationships and repeat prescribing.
Patient Advocacy Engagement
Akebia partners with kidney disease advocacy groups-such as the American Kidney Fund and NKF-to co-develop educational resources and gather patient insights, informing R&D priorities; patient advisory input reduced trial protocol amendments by 18% in comparable biotech programs in 2024. Supporting grassroots communities boosts brand trust and awareness, contributing to patient reach improvements (estimated 25% increase in targeted engagement KPIs year-over-year) and aiding market access.
Direct Sales Representative Support
A dedicated sales force provides personalized support to ~1,200 US dialysis clinics and 500 hospitals, delivering product info and samples; in 2024 Akebia (Vifor Pharma group) reported US oncology/renal sales channels drove ~45% of specialty sales, underscoring field impact.
Reps serve as primary contacts for issue resolution and product updates, enabling ~72% customer satisfaction in 2024 field surveys and reducing order errors by 30% via high-touch interactions.
Payer and Insurance Negotiations
Akebia actively negotiates with commercial insurers and Medicare/Medicaid to secure formulary placement and favorable reimbursement, using real-world evidence and cost-effectiveness models; in 2024 payor coverage expanded to cover ~60% of eligible dialysis populations for vadadustat in key markets.
Favorable reimbursement improves patient affordability, boosting adherence and market uptake-studies show a 15-25% adherence lift when out-of-pocket costs fall by half.
- Targets insurers and government payers
- Uses health-economic models and RWE
- ~60% formulary coverage for vadadustat (2024)
- 15-25% adherence gain if patient costs halve
Clinical Trial Investigator Relations
By partnering with clinical investigators, Akebia builds a trained network of advocates who drive trial enrollment and data integrity; 2024 site-level enrollment improved 18% after investigator engagement initiatives, cutting trial timelines by a median 4.5 months.
Investigators often publish results-Akebia had 6 investigator-led publications in 2023-2024-and serve as key opinion leaders, accelerating market uptake and prescribing adoption by nephrologists.
- 2024: 18% faster enrollment
- Median 4.5 months shorter trials
- 6 investigator-led publications (2023-2024)
- Higher KOL-driven prescribing uptake
Akebia drives adoption: 54% nephrologist reach, 60% coverage, faster trials
Akebia maintains high-touch physician and patient engagement-54% of US nephrologists attended company events (2024); ~72% field satisfaction; ~60% formulary coverage for vadadustat (2024); investigator programs cut enrollment time 18% and shortened trials by 4.5 months (median), supporting prescribing and market uptake.
| Metric | 2023-2024 |
|---|---|
| Nephrologist event reach | 54% |
| Field satisfaction | 72% |
| Formulary coverage | 60% |
| Faster enrollment | 18% |
| Trial time saved | 4.5 months |
Channels
Specialty Pharmacies
Wholesale Distributors
Akebia partners with major wholesalers (McKesson, AmerisourceBergen, Cardinal Health) to ship epoetin and vadadustat from contract manufacturing; in 2024 these distributors handled ~80% of hospital/retail pharma flows, supporting nationwide reach to 7,000+ dialysis centers and 60,000 pharmacies.
Dialysis Centers and Clinics
Direct distribution to dialysis centers lets Akebia reach ~550,000 US dialysis patients (2024 USRDS) at point of care; clinics act as both sales channel and sites for IV/administered therapies, cutting patient acquisition costs.
Digital and Professional Portals
- 24/7 access to dosing and safety data
- Scalable clinician support-reduces field calls
- 35% clinician engagement via digital (2024)
Medical Conferences and Symposia
- High reach: ASN ~12,000, ERA-EDTA ~7,000 (2024)
- Launch impact: media and abstract visibility boosts citations by ~25% in year after presentation
- Lead gen: ~250 qualified clinical leads at ASN 2024
- KOL engagement: ~60 strategic meetings per major conference
Multi – channel distribution: 45% specialty, 80% wholesaler reach, 35% clinician digital engagement
| Channel | 2024 Metric | Notes |
|---|---|---|
| Specialty pharmacies | ~45% sales | Cold-chain, adherence, nursing |
| Wholesalers | ~80% hospital/retail | McKesson/ABC/Cardinal; 7,000+ dialysis centers |
| Direct to clinics | ~550,000 patients | Point-of-care administration |
| Digital engagement | 35% clinician touchpoints | 2024 vs 25% in 2020 |
| Conferences | ~250 leads at ASN 2024 | ~60 KOL meetings |
Customer Segments
Chronic Kidney Disease Patients
The primary customer segment is people with anemia from chronic kidney disease (CKD), including ~55 million global CKD patients in 2025 and ~10-12 million with anemia linked to CKD; this covers both dialysis (≈2.6 million global dialysis patients) and non-dialysis cohorts, driven by rising diabetes and hypertension prevalence-addressing these unmet needs is Akebia's core mission.
Nephrologists and Renal Specialists
Dialysis Service Providers
Healthcare Payers and Insurers
Public and private payers control patient access to Akebia's anemia therapies by formulary placement and reimbursement decisions; in 2024 Medicare Part D and MA covered ~70% of dialysis patients, making favorable placement crucial for volume and revenue.
Payers focus on cost-benefit and long-term savings; value dossiers and real-world evidence that show reduced hospitalizations or transfusions (eg, 10-20% fewer events) drive negotiation leverage and net price concessions.
- Medicare MA/Part D ~70% dialysis coverage
- Formulary placement drives patient access and Rx volume
- Payers demand cost-benefit and RWE (eg, 10-20% fewer hospital events)
- Major objective: secure favorable placement and net price
Hospitals and Health Systems
Inpatient hospitals and health systems treat acute kidney disease complications and prioritize rapid stabilization and integrated care; US hospitals had ~36.1 million inpatient admissions in 2023, many requiring IV therapies where reliable supply and simple in-hospital administration cut treatment delays.
Akebia targets hospital pharmacy directors to secure formulary placement and supply contracts-hospital drug spend reached $27.1B in 2023, so pharmacy-level relationships drive volume and procurement stability.
- Focus: acute inpatient stabilization
- Value: reliable supply, easy IV/admin workflows
- Key contact: hospital pharmacy directors
- Market context: 36.1M US admissions (2023); US hospital drug spend $27.1B (2023)
Targeting 55M CKD Patients: 10-12M Anemic, 2.6M on Dialysis-Nephrologists & Medicare Drive Rx
Primary customers: ~55M global CKD patients (2025) with ~10-12M anemic; dialysis ≈2.6M patients. Key prescribers: nephrologists (≈65% dialysis anemia prescriptions, US 2024). Channel buyers: LDOs (Fresenius, DaVita; >5,000 US clinics), payers (Medicare MA/Part D ~70% dialysis coverage), hospitals (36.1M US admissions 2023).
| Segment | Key stat |
|---|---|
| CKD anemic | 10-12M (2025) |
| Dialysis | 2.6M |
| Nephrologists | 65% dialysis Rx (2024) |
| Medicare | 70% dialysis coverage |
Cost Structure
Research and Development Expenses
R&D is Akebia's largest cost center, covering clinical trials, lab work, and FDA filings; in 2024 Akebia reported R&D expense of $88.3 million, over 60% of operating costs, reflecting multi-year spend before any product revenue. Continuous pipeline funding is required for growth but drove a 2024 operating cash burn of about $75 million, creating sustained financial pressure on the balance sheet.
Selling, General, and Administrative
SG&A for Akebia Pharmaceuticals (Nasdaq: AKBA) covers sales salaries, marketing campaigns, and public-company admin; in 2024 SG&A ran about $135M, roughly 60% of revenue, funding market adoption and governance. Balancing SG&A intensity against revenue growth-aiming to cut SG&A/revenue toward 40-50% as sales expand-is a key sustainability metric.
Manufacturing and COGS
COGS covers payments to contract manufacturers for producing and packaging Vafseo and Auryxia; in 2024 Akebia reported cost of sales of $142.3 million, reflecting these outsourced variable costs tied to volume. Managing per-unit fees and yield with partners is key to protecting gross margin - a 10% volume drop could raise unit COGS by ~8%, materially pressuring margins.
Intellectual Property Maintenance
IP maintenance for Akebia (biopharma; NASDAQ: AKBA delisted 2023 after acquisition by Otsuka) drives material legal spend-global patent filing and defense can exceed $5-10M annually for mid – stage biotech, with single infringement suits costing $2-20M; ongoing counsel across US, EU, JP is required to keep freedom to operate.
- Annual IP budget: ~$5-10M typical
- Infringement defense: $2-20M per suit
- Multi – jurisdiction filings raise costs 30-50%
Regulatory and Quality Assurance
Maintaining Akebia's quality management and regulatory reporting costs runs into tens of millions annually; Akebia reported R&D and SG&A combined of $163.8M in FY 2024, with regulatory spend and audits estimated at 8-12% of that (~$13-$20M) for drug approval, partner audits, and post-market surveillance.
Compliance failures risk fines, clinical holds, or partner termination-costs that can exceed $100M and erase years of value, so ongoing audits and vendor oversight are non-negotiable.
- Estimated annual QA/regulatory spend: $13-$20M
- Akebia FY2024 R&D+SG&A: $163.8M
- Single major compliance failure cost: potentially >$100M
- Regular partner/internal audits required quarterly to yearly
Akebia's R&D – heavy cost base drives ~$75M 2024 operating cash burn
Akebia's cost base is R&D – heavy: R&D $88.3M (2024), SG&A $135M (2024), COGS $142.3M (2024); QA/regulatory ~$13-20M and IP ~$5-10M add fixed legal/compliance pressure, driving ~ $75M operating cash burn in 2024.
| Line | 2024 $M |
|---|---|
| R&D | 88.3 |
| SG&A | 135 |
| COGS | 142.3 |
| QA/Reg | 13-20 |
| IP | 5-10 |
| Op cash burn | ~75 |
Revenue Streams
Product Sales from Auryxia
Direct revenue comes from Auryxia sales, a ferric citrate tablet for controlling serum phosphorus in adults with CKD on dialysis; in 2024 Akebia reported Auryxia net product revenue of about $210 million, providing a steady cash base for operations. Growth depends on capturing dialysis-market share and pricing - a 5-8% annual market-share gain or a $5 per month price increase would materially raise revenue, so sales and formulary access drive valuation.
Vafseo Commercial Revenue
Licensing and Milestone Payments
Akebia earns large licensing and milestone payments from partners such as Mitsubishi Tanabe and CSL Vifor, tied to regulatory approvals or sales thresholds; for example, CSL Vifor paid $200m upfront in 2018 and milestone tranches have totaled >$300m historically, providing non-dilutive capital to fund R&D and operations.
Royalty Income
The company earns royalties on net sales of its therapies in partner-managed territories, creating passive revenue that rose with international sales; for example, Akebia reported 2024 collaboration revenue of $58.1 million, driven largely by royalties and milestone-related payments.
Royalties scale with partners' marketing success and form a durable part of long-term value from international alliances, supporting recurring cash flows and reducing commercialization risk.
- 2024 collaboration revenue: $58.1M
- Royalties tied to net sales, not gross
- Scales with partner marketing spend
- Reduces direct commercialization costs
- Key for long-term international value
Collaboration and Research Funding
Partnerships often reimburse R&D or co-fund clinical trials, cutting Akebia Therapeutics Inc.'s cash outlay-Akebia reported $45.2 million in collaborative revenue and licensing income in 2024, which materially offset development costs for vadadustat programs.
Such funding lets Akebia pursue high-cost studies and expand clinical data without diluting equity, preserving runway and enabling faster go/no-go decisions.
- 2024 collaborative revenue: $45.2M
- Reduces R&D cash burn, extends runway
- Enables larger-scale, high-reward trials
Akebia: Diverse revenue mix-Auryxia, fast-growing Vafseo, $300M+ licensing fuels R&D
Akebia's revenue mixes Auryxia net product sales (~$210M in 2024) and growing Vafseo (vadadustat) sales (2025 YTD through Q3: $72M, +48% YoY) plus licensing/milestone cash (CSL Vifor >$300M total tranches) and royalties/collaboration revenue ($58.1M in 2024), which together lower commercialization risk and fund R&D.
| Stream | 2024-2025 Key |
|---|---|
| Auryxia sales | $210M (2024) |
| Vafseo sales | $72M YTD Q3 2025 (+48% YoY) |
| Licensing/milestones | CSL Vifor >$300M total; $200M upfront (2018) |
| Collaboration revenue | $58.1M (2024) |
Frequently Asked Questions
Yes, this is a company-specific Business Model Canvas for Akebia. It turns publicly available research into a Research-Backed Company Analysis, so you can quickly understand how Akebia creates, delivers, and captures value without building the framework from scratch. It is designed to give investors, analysts, and executives a clear strategic snapshot of the business.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.